Hansa Medical AB Patent applications |
Patent application number | Title | Published |
20140187503 | DIAGNOSTIC METHOD - It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis. | 07-03-2014 |
20140080754 | DIAGNOSTIC METHOD FOR BACTERIAL MENINGITIS - It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis. | 03-20-2014 |
20140065128 | TREATMENT FOR IgE-MEDIATED DISEASE - The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies. | 03-06-2014 |
20130252347 | DIAGNOSTIC METHOD - It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis. | 09-26-2013 |
20130177547 | ANCESTRAL SERINE PROTEASE COAGULATION CASCADE EXERTS A NOVEL FUNCTION IN EARLY IMMUNE DEFENSE - The present invention relates to blood coagulation factor XIII (FXIII) for treatment and/or prevention of an infection by a microorganism and/or the symptoms associated with said infection, a pharmaceutical composition comprising a pharmaceutically effective amount of said FXIII, a method for the manufacture of a medicament comprising a pharmaceutically effective amount of said FXIII, and a method of treatment comprising administering to a patient in need a pharmaceutically effective amount of said FXIII. | 07-11-2013 |
20110318340 | DEGLYCOSYLATED ANTIBODIES - The present invention provides an antibody, or antibody fragment, with modified glycosylation for use in treating or preventing a disease or condition, where the antibody or fragment: (a) suppresses an inflammatory condition forming part of the disease or condition to be treated or prevented; and/or (b) displays increased efficacy and/or decreased side effects in comparision to treatment or prevention with the corresponding antibody with unmodified glycosylation. | 12-29-2011 |
20100135981 | USE OF THE ENDOGLYCOSIDASE ENDOS FOR TREATING IMMUNOGLOBULIN G MEDIATED DISEASES - The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies. | 06-03-2010 |